Last reviewed · How we verify
Clobetasol Propionate 0.05% Foam
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body), Psoriasis, Eczema.
At a glance
| Generic name | Clobetasol Propionate 0.05% Foam |
|---|---|
| Also known as | Olux® Foam |
| Sponsor | Galderma R&D |
| Drug class | Topical corticosteroid (Class I/super-potent) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory cytokines, reduced immune cell infiltration, and suppression of local inflammatory cascades. The foam formulation provides enhanced penetration and coverage for scalp and body surface conditions. It is indicated for short-term treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body)
- Psoriasis
- Eczema
- Lichen planus
- Other steroid-responsive dermatologic conditions
Common side effects
- Skin atrophy
- Telangiectasia
- Striae
- Folliculitis
- Hypertrichosis
- Acneiform eruptions
- Hypopigmentation
- Perioral dermatitis
Key clinical trials
- A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam (PHASE4)
- Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams
- Subject Preference for Scalp Psoriasis Treatment (PHASE3)
- Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis (PHASE3)
- Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. (PHASE4)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
- Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis (PHASE4)
- A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clobetasol Propionate 0.05% Foam CI brief — competitive landscape report
- Clobetasol Propionate 0.05% Foam updates RSS · CI watch RSS
- Galderma R&D portfolio CI